Completed PHASE4 INTERVENTIONAL 2-arm NCT01464229

Iloperidone Augmentation of SSRIs for Patients With Major Depressive Disorder With Residual Anger and Irritability

A Placebo-Controlled Crossover Study of Iloperidone Augmentation of SSRIs for Residual Anger and Irritability in Major Depressive Disorder

Sponsor: Maurizio Fava, MD

Conditions Major Depressive Disorder

Interventions Iloperidone Placebo

Updated 9 times since 2017 Last updated: Feb 28, 2017 Started: Apr 30, 2012 Primary completion: Dec 31, 2014 Completion: Dec 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE4 clinical study on Major Depressive Disorder, this trial is completed. The trial is conducted by Maurizio Fava, MD and has accumulated 9 data snapshots since 2012. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2023 — Jul 2024 [monthly]

Completed PHASE4
Dec 2022 — Jan 2023 [monthly]

Completed PHASE4
Jan 2021 — Dec 2022 [monthly]

Completed PHASE4

▶ Show 4 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
May 2017 — Jun 2018 [monthly]

Completed PHASE4
Feb 2017 — May 2017 [monthly]

Completed PHASE4
Jan 2017 — Feb 2017 [monthly]

Completed PHASE4

First recorded

Apr 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Maurizio Fava, MD
Novartis Pharmaceuticals

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States